OpGen, Inc. (OPGN) Trading 3.8% Higher
OpGen, Inc. (NASDAQ:OPGN) shares traded up 3.8% during mid-day trading on Friday . The stock traded as high as $0.29 and last traded at $0.27. 718,971 shares were traded during mid-day trading, a decline of 36% from the average session volume of 1,130,853 shares. The stock had previously closed at $0.26.
Several research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $1.00 price target on shares of OpGen in a research note on Tuesday, October 24th. Zacks Investment Research lowered shares of OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, September 13th.
The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 0.19.
An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned approximately 2.72% of OpGen as of its most recent filing with the Securities and Exchange Commission. 10.90% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/17/opgen-inc-opgn-trading-3-8-higher.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.